Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The adenylate cyclase pathway downstream of dopamine receptors is a fundamental signaling mechanism in the brain that translates extracellular dopamine signals into intracellular responses (Beaulieu & Gainetdinov, 2011). This pathway is bifurcated based on the type of dopamine receptor activated: D1-like receptors (D1 and D5) couple to stimulatory G-proteins (Gs/olf) to activate adenylate cyclase, increasing the production of the second messenger cyclic AMP (cAMP) (Neve et al., 2004). Conversely, D2-like receptors (D2, D3, and D4) couple to inhibitory G-proteins (Gi/o) to suppress adenylate cyclase activity and reduce cAMP levels (Missale et al., 1998). These fluctuations in cAMP regulate protein kinase A (PKA) activity, which in turn modulates various downstream targets, including ion channels, transcription factors like CREB, and the phosphoprotein DARPP-32 (Greengard, 2001). This signaling cascade is vital for motor control, motivation, and cognitive functions, and its dysfunction is a hallmark of major neurological and psychiatric conditions such as Parkinson's disease and schizophrenia (StatPearls, 2023). Therapeutic strategies often focus on using dopamine receptor ligands to restore balance within this pathway by either augmenting or inhibiting the production of cAMP.
Modulation of intracellular cyclic AMP (cAMP) levels through the activation or inhibition of adenylate cyclase by G-protein coupled dopamine receptors (Beaulieu & Gainetdinov, 2011).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adenylate cyclase pathway downstream of dopamine receptors.